BioSpace Feature: Advancing Cyclic Peptides from Discovery to Scalable Manufacturing

News

}

Home / News / Company News / Company News detail

Time: 2026-09-16

Source: Viva Biotech

[Abstract]:In a recent BioSpace feature, Viva Biotech experts discuss cyclic peptide discovery, development and manufacturing.

Cyclic peptides are gaining momentum as a therapeutic modality, with the potential to combine the oral convenience of small molecules with antibody-like selectivity. Their development, however, still requires careful optimization of bioavailability, PK, synthesis reproducibility, impurity control and scale-up.

In a recent BioSpace feature, Viva Biotech experts Dr. Susan Chen, Chief Technology Officer, and Dr. Yue Qian, VP & Head of MARS Division, discuss how AI-enabled peptide design, ADME/PK modeling and hybrid SPPS/LPPS synthesis strategies can support peptide discovery and development. Viva's hybrid synthesis approach has also been applied to kilogram-scale GLP-1 analogue preparation at ≥99% purity.

The article also explores the importance of connecting discovery with downstream development and manufacturing early, highlighting Viva Biotech's integrated capabilities across AI-enabled design, peptide synthesis, process development, analytics, formulation and manufacturing.

Read the full BioSpace article:
https://www.biospace.com/drug-development/cyclic-peptides-open-new-drug-frontiers-if-manufacturing-can-keep-up

Previous Page：Enabling Carbene Chemistry Exploration: Synthetic Strategies for Diazirines Next Page：Unlocking TPD Modality Bottlenecks | One-Stop CRO Platform Empowers New-Drug Discovery of PROTACs, Molecular Glues and RIPTACs

Back

Media contact: vivapr@vivabiotech.com

This site uses cookies and your privacy choices are important to us

We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.